Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility.
about
Recent developments in adenosine receptor ligands and their potential as novel drugsAdenosine A(2A) Receptor Antagonists and Parkinson's DiseaseEvaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure.Pharmacochemistry of the platelet purinergic receptors.Immune cell regulation by autocrine purinergic signalling.Xanthines as adenosine receptor antagonists.3-(Fur-2-yl)-10-(2-phenylethyl)-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one, a novel adenosine receptor antagonist with A(2A)-mediated neuroprotective effects.GPCR ligand dendrimer (GLiDe) conjugates: adenosine receptor interactions of a series of multivalent xanthine antagonistsSynergistic effects of polyphenols and methylxanthines with Leucine on AMPK/Sirtuin-mediated metabolism in muscle cells and adipocytes[18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodentsIntroduction to adenosine receptors as therapeutic targets.Modulation of G protein-coupled adenosine receptors by strategically functionalized agonists and antagonists immobilized on gold nanoparticles.Bench-to-bedside review: adenosine receptors--promising targets in acute lung injury?Adenosine neuromodulation and traumatic brain injury.Adenosine receptors as drug targets.Adenosine receptor targeting in health and disease.Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands.History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents.Radical C-H functionalization to construct heterocyclic compounds.Pyrazin-2(1H)-ones as a novel class of selective A3 adenosine receptor antagonists.Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer.Hydration Site Thermodynamics Explain SARs for Triazolylpurines Analogues Binding to the A2A ReceptorA3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.Caffeine alters cytokine secretion by PBMC induced by colon cancer cells.Synthesis of purine modified 2'-C-methyl nucleosides as potential anti-HCV agents.Discovery of 3,4-Dihydropyrimidin-2(1H)-ones As a Novel Class of Potent and Selective A2B Adenosine Receptor Antagonists.A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin.Adenosine and its receptors as therapeutic targets: An overview.Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates.Chalcone-based derivatives as new scaffolds for hA3 adenosine receptor antagonists.2-Amino[1,2,4]triazolo[1,5-c]quinazolines and Derived Novel Heterocycles: Syntheses and Structure-Activity Relationships of Potent Adenosine Receptor Antagonists.Synthesis, adenosine receptor binding and molecular modelling studies of novel thieno[2,3-d]pyrimidine derivatives.Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine functionalized congeners.Unfolding Role of a Danger Molecule Adenosine Signaling in Modulation of Microbial Infection and Host Cell Response.Biochemical and Pharmacological Role of A1 Adenosine Receptors and Their Modulation as Novel Therapeutic Strategy.Targeting adenosine receptors with coumarins: synthesis and binding activities of amide and carbamate derivatives.Synthesis of adenosine analogues with indole moiety as human adenosine A3 receptor ligands.Concise Xanthine Synthesis through a Double-Amidination Reaction of a 6-Chlorouracil with Amidines using Base-Metal Catalysis.Characterization of adenosine receptor in its native environment: insights from molecular dynamics simulations of palmitoylated/glycosylated, membrane-integrated human A(2B) adenosine receptor.Progress in the development of small molecules as new human A3 adenosine receptor ligands based on the 3-thiophenylcoumarin core
P2860
Q27687253-88B2E2D7-544E-44DF-AC36-5635385E42B4Q29346492-C7440F95-18AB-43D5-8D53-C309A31C5872Q30376612-B76C0F9E-5A10-4069-9F65-8E351CF7EEFCQ33869922-6835454D-475A-4E71-A70C-2D768C871F3FQ34025783-3514270D-33A9-4AC9-B012-3505D172003BQ34139398-7F486964-602D-4E12-81BC-ED1DAF1CF7C7Q34365007-B62C7FF5-F8F9-4803-A11A-CFD1FFF30C57Q35048339-1E24F764-7C28-4169-AEAD-BC18A741FF83Q35097761-57F4002F-0AFF-4E46-88AC-9EAF7D3AA918Q35148312-2B06580F-5A56-4227-9EA0-835A5FA3021BQ36153376-7E1AECDB-C16F-4746-A269-4E6137ED1001Q36821548-2B7F11D1-74C7-48D7-AD98-7E336320D15CQ37284017-F1100008-DA4B-4955-AB26-5FBEBF8C3EDDQ37402676-9FFD6F11-3FBF-420E-8CB2-98B31864BFE7Q37691817-E52D414B-49A9-4D98-83AF-C571DFD5690EQ37948081-9D83504C-9BD7-4480-9FFC-C03F07C8245CQ37995704-01B8FA26-AB5D-4519-86C7-26E46F43B06DQ38395423-BB103101-1B39-4E85-BB75-DC4CABDE46E6Q38685868-7DA449A9-E561-4284-B6EB-C9DA357B9F75Q38979023-081A2978-3941-4A95-BBCF-25246B31663FQ39148961-F37E6E59-BB21-4A1B-88EF-8383D7A2AE33Q39159119-FDCD3B52-9D14-4752-80C2-3950C1698A8EQ39418010-E9AF1F7D-627D-4375-8FDC-89E205D6234FQ39431839-C5D0B2DF-B456-48B6-BCCF-F09BC3A91BC7Q39461131-F9BA6DC2-C4D0-4551-B161-13C70E487F59Q39775269-0653EDC8-0034-4EAC-9309-98D35ED72E15Q39793029-0F96B1AD-9C5F-4317-8D69-7FCF4533C360Q42059361-4B2A90CC-979F-4F2A-8459-FF962D8D1893Q42952282-FE2934D8-6AE1-4506-B6B5-C25728236491Q43944774-8D2FECF9-A517-4061-8483-899A40F9088CQ46475985-4EA2E1EC-2266-4CFF-9B16-738FEDAD97D2Q47384028-D546A829-9087-4C41-B673-059CC8CF5368Q47751959-85F51410-40FB-4C07-86CA-E2471F028E04Q48284423-4EF45FA0-D1F0-4372-8A84-D5C41BB704E9Q48732639-DF46C494-E43A-4A52-BBE8-F01DF15CC3B0Q51755796-05A058DC-3CF3-4FF5-B0ED-2875CB0A2A5EQ52668081-9D14088A-D5A2-41D7-9BE9-AF98E7070B8BQ53130318-B3E77DD9-9D6F-44CF-83BB-9FB75A0F303AQ53437158-9290573E-6797-499E-B266-1D0F09D1E4B2Q56990834-35E7F3CB-E614-40CE-A079-0EECE31DC21A
P2860
Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Adenosine receptor antagonists ...... acology into clinical utility.
@ast
Adenosine receptor antagonists ...... acology into clinical utility.
@en
Adenosine receptor antagonists ...... acology into clinical utility.
@nl
type
label
Adenosine receptor antagonists ...... acology into clinical utility.
@ast
Adenosine receptor antagonists ...... acology into clinical utility.
@en
Adenosine receptor antagonists ...... acology into clinical utility.
@nl
prefLabel
Adenosine receptor antagonists ...... acology into clinical utility.
@ast
Adenosine receptor antagonists ...... acology into clinical utility.
@en
Adenosine receptor antagonists ...... acology into clinical utility.
@nl
P2093
P356
P1433
P1476
Adenosine receptor antagonists ...... acology into clinical utility.
@en
P2093
Mojgan Aghazadeh Tabrizi
Pier Andrea Borea
Pier Giovanni Baraldi
Stefania Gessi
P304
P356
10.1021/CR0682195
P577
2008-01-01T00:00:00Z